Lupin is currently trading at RS 2065.00, up by 12.10 points or 0.59% from its previous closing of RS 2052.90 on the BSE.

The stock opened at RS 2045.95 and touched a high of RS 2065.00 and a low of RS 2045.95 so far. A total of 2444 shares have been traded on the counter.

The BSE Group 'A' stock with a face value of RS 2 has recorded a 52-week high of RS 2403.45 on 02-Jan-2025 and a 52-week low of RS 1774.00 on 07-Apr-2025.

In the past week, the stock’s high and low stood at RS 2068.70 and RS 1972.05 respectively. The company’s current market capitalization is RS 93946.85 crore.

Promoters hold 46.90% stake in the company, while Institutions and Non-Institutions hold 47.06% and 6.06% respectively.

Lupin has launched Risperidone Extended-Release Injectable Suspension (25 mg, 37.5 mg, and 50 mg single-dose vials) with 180-day CGT exclusivity in the U.S., following approval from the United States Food and Drug Administration (USFDA). This marks Lupin’s first product developed using the proprietary PrecisionSphere technology from Nanomi B.V., its subsidiary.

Nanomi’s Long-Acting Injectable (LAI) platform has demonstrated strong efficacy and safety in drug delivery. Its PrecisionSphere technology produces uniform microspheres for extended drug release over weeks to months, supports improved injectability using smaller needles, and ensures consistent drug concentrations. Lupin is also expanding the technology’s reach by collaborating with companies aiming to extend their product lifecycles.

Lupin is an innovation-driven global pharmaceutical company engaged in the production, development, and marketing of a wide range of branded and generic formulations, biotechnology products, and active pharmaceutical ingredients (APIs).